AbbVie Inc (ABBV)vsElevance Health Inc (ELV)
ABBV
AbbVie Inc
$202.78
-0.18%
HEALTHCARE · Cap: $368.38B
ELV
Elevance Health Inc
$381.75
-1.02%
HEALTHCARE · Cap: $86.31B
Smart Verdict
WallStSmart Research — data-driven comparison
Elevance Health Inc generates 219% more annual revenue ($200.42B vs $62.82B). ABBV leads profitability with a 5.8% profit margin vs 2.6%. ABBV appears more attractively valued with a PEG of 0.56. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ELV
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-23.7%
Fair Value
$168.52
Current Price
$202.78
$34.26 premium
Margin of Safety
+60.5%
Fair Value
$1011.01
Current Price
$381.75
$629.26 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Generating 4.1B in free cash flow
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
2.6% revenue growth
2.6% margin — thin
Weak financial health signals
Earnings declined 16.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.56 suggests the stock is reasonably priced for its growth.
Bull Case : ELV
The strongest argument for ELV centers on Market Cap, P/E Ratio, Price/Book. PEG of 1.45 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 102.2x leaves little room for execution misses.
Bear Case : ELV
The primary concerns for ELV are Revenue Growth, Profit Margin, Piotroski F-Score. Thin 2.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
ELV carries more volatility with a beta of 0.67 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ELV generates stronger free cash flow (4.1B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 56/100) and 12.4% revenue growth. ELV offers better value entry with a 60.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Elevance Health Inc
HEALTHCARE · HEALTHCARE PLANS · USA
Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?